Meiji (OTCMKTS:MEJHY) & ChromaDex (NASDAQ:CDXC) Financial Survey

ChromaDex (NASDAQ:CDXC) and Meiji (OTCMKTS:MEJHY) are both consumer defensive companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

15.4% of ChromaDex shares are held by institutional investors. 9.6% of ChromaDex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for ChromaDex and Meiji, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChromaDex	0	0	2	0	3.00
Meiji	0	0	0	0	N/A

ChromaDex currently has a consensus target price of $6.00, indicating a potential upside of 80.72%. Given ChromaDex’s higher possible upside, analysts clearly believe ChromaDex is more favorable than Meiji.

Valuation & Earnings

This table compares ChromaDex and Meiji”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChromaDex	$85.58 million	2.93	-$4.94 million	($0.05)	-66.40
Meiji	N/A	N/A	N/A	$74.24	0.17

Meiji has lower revenue, but higher earnings than ChromaDex. ChromaDex is trading at a lower price-to-earnings ratio than Meiji, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChromaDex and Meiji’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ChromaDex	-1.58%	-4.68%	-2.50%
Meiji	N/A	N/A	N/A

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

About Meiji

Meiji Holdings Co., Ltd., through its subsidiaries, engages in the manufacture and sale of dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, cheese, drinking milk, beverages, butter, margarine, cream, ice cream, frozen food, chocolates, gummy, chewing gums, sports nutrition products, protein, infant formula, enteral formula, beauty supplements, OTC drugs, feed stuffs, sugar, and corn sweeteners. The company also offers ethical pharmaceutical products, including drugs for infectious and CNC disorders, vaccines, blood plasma products, generic drugs, and animal health products. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.